Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 5/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865832 | 0.74 | KDM4E (0.35) | MAPTPKMCDK4CASRHSD17B10 | |
| SCHEMBL28736752 | 0.71 | ALDH1A1 (0.63) | MAPTPARP1TNKSTNKS2HSD17B10 | |
| SCHEMBL6232605 | 0.69 | ALDH1A1 (0.48) | MAPTPARP1TNKSTNKS2 | |
| SCHEMBL13865866 | 0.67 | MAPT (0.49) | MAPTPARP1PKMCDK4AURKA | |
| SCHEMBL13865826 | 0.64 | MAPT (0.32) | MAPTPKMMAPK1RAB9AATM | |
| SCHEMBL31448409 | 0.64 | MAPT (0.71) | MAPTPKMHSD17B10MAPK1RAB9A | |
| SCHEMBL28694505 | 0.62 | MAPT (0.68) | MAPTPKMHSD17B10MAPK1RAB9A | |
| SCHEMBL6366681 | 0.62 | TLR8 (0.40) | PARP1CASRHSD17B10RAB9A | |
| SCHEMBL353025 | 0.61 | CYP1A2 (0.59) | AURKAHSD17B10RAB9A | |
| SCHEMBL11304574 | 0.61 | GSR (0.45) | MAPTHSD17B10MAPK1RAB9ATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | MAPT 4476/4885PARP1 2039/4885PKM 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.